February 14, 2022
Life Sciences
  • The FDA delayed its decision on authorizing Pfizer-BioNTech’s COVID-19 vaccine for children under five years old. The agency stated, “Based on the agency’s preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.” The companies said they don’t expect to have three-dose protection data available until early April. (Articles here, here, here, and here)